Trial Profile
Phase I, pharmacokinetic study of single escalating dose of GSK2256294 in healthy male subjects or obese smokers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2015
Price :
$35
*
At a glance
- Drugs GSK 2256294 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- 04 Dec 2015 New trial record
- 01 Dec 2015 Results published in the British Journal of Clinical Pharmacology